COMUNICADO: Gerresheimer Ascends to the MDAX

 

COMUNICADO: Gerresheimer Ascends to the MDAX

Actualizado 04/12/2008 10:39:31 CET

DÜSSELDORF, Germany, December 4 /PRNewswire/ --

-- Gerresheimer Stock Becomes Even More Attractive Through Inclusion in MDAX on December 22, 2008

-- On September 6, 2007 Gerresheimer was Already Included in the SDAX Ahead of the Normal Scheduling Process

Gerresheimer stock will be included in the MDAX Index on December 22, 2008. This was decided by the Management Board of the German Stock Exchange late on Wednesday evening in the course of the review of the selection indices.

Gerresheimer AG has been listed in the Prime Standard of the Frankfurt Stock Exchange since June 11, 2007 after one of the largest IPOs of the year, with a total issue volume in excess of EUR900 million. Already, on September 6, 2007, Gerresheimer was included in the SDAX Index ahead of the normal scheduling process.

"Inclusion in the index confirms Gerresheimer's outstanding development. As an MDAX constituent our company is now even more attractive for national as well as international investors and attracts the attention of the capital market to an increased degree," says Dr. Axel Herberg, CEO of Gerresheimer AG.

In the first nine months of the financial year 2008 (December 2007 to August 2008), sales increased markedly by 12.3 % to EUR783.4m (prior year period: EUR697.4m). Operating results (adjusted EBITDA) to the end of August actually improved by 18.1 % to EUR146.9m (EUR124.4m). The adjusted EBITDA margin was 18.8 %, a full percentage point higher than in the comparable period of the prior year.

About Gerresheimer

Gerresheimer employs more than 10,000 people in 40 locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR958m. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.


Contact Press
Burkhard Lingenberg
Director Corporate PR & Marketing
Telephone +49-211-6181-250
Telefax +49-211-6181-241
E-mail b.lingenberg@gerresheimer.com

Contact Investor Relations
Anke Linnartz
Director Corporate Investor Relations
Telephone +49-211-6181-314
Telefax +49-211-6181-121
E-mail a.linnartz@gerresheimer.com

Contact Press: Burkhard Lingenberg, Director Corporate PR & Marketing, Telephone +49-211-6181-250,Telefax +49-211-6181-241, E-mail b.lingenberg@gerresheimer.com; Contact Investor Relations: Anke Linnartz, Director Corporate Investor Relations, Telephone +49-211-6181-314, Telefax +49-211-6181-121, E-mail a.linnartz@gerresheimer.com

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies